BioSpace News Archive

TFF Pharmaceuticals, Inc. announced that it has entered into a CRADA with the U.S. Army Medical Research Institute of Infectious Diseases, part of the U.S. Army Medical Research and Development Command and the U.S Army’s premier institution and facility for defensive research into countermeasures against biological warfare, and The Geneva Foundation, a non-profit that advances innovative medical research within the U.S. military.

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.

Harmony Biosciences Holdings, Inc. today announced applications open on “World Sleep Day”, Friday, March 18, 2022, for its Patients at the Heart Program.

Triumvira Immunologics today announced the completion of an extension of its Series A financing, bringing the total round to approximately $100 million.

Babson Diagnostics today announced its laboratory has been awarded accreditation by the College of American Pathologists (CAP) based on the results of a recent site inspection.

Ginkgo Bioworks announced today that it plans to host a presentation and Q&A session reviewing business performance for the fourth quarter and full year ended December 31, 2021.

Invea Therapeutics, Inc. announced that an abstract entitled, “Using An Artificial Intelligence and Machine Learning Platform to Identify Mast Cell-Focused Therapeutic Targets for Gut-Brain Axis Disorders,” has been accepted for a poster presentation at the Keystone Symposia Gut-Brain Axis, and a second abstract entitled, “AI-Based Deconvolution of the Gut-Brain Axis and its Therapeutic Implications,” has been accepted for a poster presentation at Digestive Disease Week.

Enveda Biosciences, a leading biotechnology company harnessing nature’s chemistry to develop next-generation small molecule therapies, announced the addition of three leaders to further scale and accelerate its translational drug development efforts.

Guardant Health, Inc. today provided the following statement regarding a lawsuit filed by Illumina that seeks to challenge Guardant Health’s ownership and authorship of a portion of its intellectual property and to suppress competition in the market.

Supernus Pharmaceuticals, Inc., a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, filed a notification of Late Filing on Form 12b-25 on March 1, 2022, indicating that the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2021 would be delayed.